PHARMACOKINETICS OF DIAZIQUONE AFTER 3 DIFFERENT DOSAGE REGIMENS
- 1 December 1985
- journal article
- research article
- Vol. 69 (12) , 1383-1385
Abstract
Diaziquone (AZQ) is a benzoquinone derivative exhibiting significant effects against CNS tumors. This study investigates the pharmacokinetics of AZQ for three different durations of continuous iv infusions, over 20 mins, 4 hrs, and 6 hrs, in nine patients with CNS malignancies. Total AZQ doses varied from 10 to 20 mg. The average elimination half-life was 37.2 .+-. 13.9 mins, the total clearance was 515 .+-. 280 ml/min or 11.3 .+-. 5.9 ml/min/kg, and the apparent volume of distribution by area was 26.5 .+-. 14.7 L or 0.62 .+-. 0.50 L/kg. Peak concentradtions after the 20-min infusions (three patients) varied from 0.58 to 1.20 .mu.g/ml, whereas concentrations during the 4-hr infusions (three patients) varied from 0.02 to 0.37 .mu./ml, and during the 6-hr infusions (three patients) varied from 0.02 to 0.61 .mu.g/ml. These results indicate that concentrations found to exhibit minimum inhibitory effects in in vitro cell studies are achievable during prolonged iv infusions of AZQ.This publication has 6 references indexed in Scilit:
- Treatment of patients with recurrent primary brain tumors with AZQNeurology, 1984
- Clinical pharmacology of 2,5′-diaziridinyl-3,6-biscarboethoxyamino-1,4-benzoquinone (AZQ)European Journal of Cancer and Clinical Oncology, 1983
- PHASE-II AND PHARMACOKINETIC STUDY OF AZIRIDINYLBENZOQUINONE [2,5-DIAZIRIDINYL-3,6-BIS(CARBOETHOXYAMINO)-1,4-BENZOQUINONE, DIAZIQUONE, NSC-182986] IN HIGH-GRADE GLIOMAS1983
- PHASE-I EVALUATION AND PHARMACOKINETICS OF AZIRIDINYLBENZOQUINONE USING A WEEKLY INTRAVENOUS SCHEDULE1983
- Diaziquone, 2,5-diaziridinyl-3,6-biscarboethoxyamino-1,4-benzoquinone, plasma and cerebrospinal fluid kineticsClinical Pharmacology & Therapeutics, 1982
- PHASE-I TRIAL AND PHARMACOKINETICS OF AZIRIDINYLBENZOQUINONE (NSC-182986) IN HUMANS1982